Press release
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Relapsed/Refractory Acute Myeloid Leukemia Overview
Relapsed/Refractory Acute Myeloid Leukemia Myeloid Leukemia which means the leukemia has come back after treatment and remission. Refractory AML means the leukemia did not respond to treatment. AML relapse affects about 50% of all patients who achieved remission after initial treatment, and can occur several months to several years after treatment. Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis and treatment remains challenging.
"Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Market.
The Relapsed/Refractory Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Relapsed/Refractory Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years. Relapsed/Refractory Acute Myeloid Leukemia Key players such as - Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, Glyco Mimetics, AROG Pharmaceuticals, and others, are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment
• Relapsed/Refractory Acute Myeloid Leukemia Emerging therapies such as - CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others are expected to have a significant impact on the Relapsed/Refractory Acute Myeloid Leukemia market in the coming years.
• In January 2021 Apollomics and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML)
• In October 2021 Apollomics initiated a Phase III randomized, double-blinded bridging trial to evaluate the efficacy of Uproleselan administered with chemotherapy versus chemotherapy alone in chinese patients with Relapsed/Refractory Acute Myeloid Leukemia.
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Product Type
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Product Type
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Molecule Type
• Relapsed/Refractory Acute Myeloid Leukemia by Stage and Molecule Type
DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Get a Free Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Relapsed/Refractory Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:
• CYAD-02: Celyad Oncology
• FHD-286: Foghorn Therapeutics
• AB8939: AB Science
• ONC201: Oncoceutics
• Sarclisa: Sanofi
• TCB008: TC Biopharm
• Keytruda: Merck & Co
• Uproleselan: Glyco Mimetics
• Crenolanib: AROG Pharmaceuticals
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis:
The Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
• Relapsed/Refractory Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Relapsed/Refractory Acute Myeloid Leukemia product details are provided in the report. Download the Relapsed/Refractory Acute Myeloid Leukemia pipeline report to learn more about the emerging Relapsed/Refractory Acute Myeloid Leukemia therapies at:
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Drivers
• Rising incidence of Acute Myeloid Leukemia
• Advancements in pharmacology and molecular biology to promote drug development
• Rising geriatric population
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Barriers
• High cost associated with the management of acute myeloid leukemia
• Side effects associated with the acute myeloid leukemia treatment
Scope of Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drug Insight
• Coverage: Global
• Key Relapsed/Refractory Acute Myeloid Leukemia Companies: Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, Glyco Mimetics, AROG Pharmaceuticals, and others
• Key Relapsed/Refractory Acute Myeloid Leukemia Therapies: CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and Relapsed/Refractory Acute Myeloid Leukemia emerging therapies
• Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics: Relapsed/Refractory Acute Myeloid Leukemia market drivers and Relapsed/Refractory Acute Myeloid Leukemia market barriers
Request for Sample PDF Report for Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Relapsed/Refractory Acute Myeloid Leukemia Report Introduction
2 Relapsed/Refractory Acute Myeloid Leukemia Executive Summary
3 Relapsed/Refractory Acute Myeloid Leukemia Overview
4 Relapsed/Refractory Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment
5 Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics
6 Relapsed/Refractory Acute Myeloid Leukemia Late Stage Products (Phase II/III)
7 Relapsed/Refractory Acute Myeloid Leukemia Mid Stage Products (Phase II)
8 Relapsed/Refractory Acute Myeloid Leukemia Early Stage Products (Phase I)
9 Relapsed/Refractory Acute Myeloid Leukemia Preclinical Stage Products
10 Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Assessment
11 Relapsed/Refractory Acute Myeloid Leukemia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Relapsed/Refractory Acute Myeloid Leukemia Key Companies
14 Relapsed/Refractory Acute Myeloid Leukemia Key Products
15 Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
16 Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers
17 Relapsed/Refractory Acute Myeloid Leukemia Future Perspectives and Conclusion
18 Relapsed/Refractory Acute Myeloid Leukemia Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia drugs and therapies- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Relapsed/Refractory Acute Myeloid Leukemia Market https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Relapsed/Refractory Acute Myeloid Leukemia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2912491 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Myeloid
Evolving Market Trends In The Acute Myeloid Leukemia Industry: Innovative Resear …
The Acute Myeloid Leukemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Acute Myeloid Leukemia Market Size During the Forecast Period?
The market size for acute myeloid leukemia has experienced robust growth in the past few years. A rise from a value…
Major Force in the Chronic Myeloid Leukemia Treatment Market 2025: Rising Incide …
How Will the Chronic Myeloid Leukemia Treatment Market Grow, and What Is the Projected Market Size?
The chronic myeloid leukemia treatment market has seen strong growth in recent years. It is expected to grow from $9.2 billion in 2024 to $9.76 billion in 2025, with a CAGR of 6.2%. This increase can be attributed to the rising incidence of chronic myeloid leukemia, greater awareness of cancer treatments, government initiatives, and increased…
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook Report 2024
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Relapsed/Refractory…
Acute Myeloid Leukemia Pipeline Unveiled: Pioneering Efforts in Acute Myeloid Le …
The Acute Myeloid Leukemia Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Acute Myeloid Leukemia treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the pipeline landscape and fostering the potential growth of Acute Myeloid Leukemia therapeutic advancements.
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
• DelveInsight's Acute Myeloid Leukemia pipeline…
Acute Myeloid Leukemia Market - Shattering Limits, Renewing Hope: Advancing the …
Newark, New Castle, USA - new report, titled Acute Myeloid Leukemia Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Acute Myeloid Leukemia market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Acute Myeloid Leukemia market. The report offers an overview of…
